Webinar | Why 95% of AI Projects Stall – and How Agentic AI Changes the Game
Clinical development has always been expensive. But in 2026, the economics are drawing sharper attention. Developing a single new molecular entity now routinely requires between
Modern clinical trials generate data continuously, from the moment the first patient is enrolled. Yet most data management teams are still built around workflows designed
The drug development industry is moving faster than ever, and timelines are continuing to shorten across parts of the process. AI is increasingly being applied
Ask any clinical operations leader where study startup time disappears, and the answer rarely points to a single dramatic failure. More often, the culprit is
Clinical trials generate enormous amounts of data. For decades, the industry has relied on a familiar approach to keep that data clean through rules, edit
The period immediately following Data Base Lock (DBL) is often the most stressful window in a clinical trial. While the “hard work” of data collection
In the high-stakes environment of clinical development, the burden of documentation has reached a tipping point. Medical writers and clinical teams are increasingly sidelined by
According to the Tufts Center for the Study of Drug Development, the average clinical trial can take 7–10 years from discovery to approval, and delays
If you read Part 1 of this series, you’ve already seen how Interactive Review Listings (IRLs) simplify and speed up the core data review process.
Get our perspectives on AL/ML in the life sciences industry directly to your inbox.
